Hennion & Walsh Asset Management, Inc. Anavex Life Sciences Corp. Transaction History

Hennion & Walsh Asset Management, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 27, 2023	SELL	$6.55 - $9.37 $77,008 - $110,163	-11,757 Reduced 16.49%	59,550 $390,000
Q2 2023 Aug 09, 2023	BUY	$7.66 - $9.5 $5,737 - $7,115	749 Added 1.06%	71,307 $580,000
Q1 2023 Apr 20, 2023	SELL	$8.32 - $11.75 $13,794 - $19,481	-1,658 Reduced 2.3%	70,558 $605,000
Q4 2022 Jan 12, 2023	BUY	$7.65 - $14.43 $44,041 - $83,073	5,757 Added 8.66%	72,216 $669,000
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $19,838 - $28,664	-2,229 Reduced 3.25%	66,459 $686,000
Q2 2022 Jul 19, 2022	BUY	$7.31 - $12.84 $48,457 - $85,116	6,629 Added 10.68%	68,688 $688,000
Q1 2022 Apr 26, 2022	BUY	$9.74 - $17.69 $238,659 - $433,458	24,503 Added 65.24%	62,059 $764,000
Q4 2021 Feb 14, 2022	BUY	$16.88 - $23.31 $633,945 - $875,430	37,556 New	37,556 $651,000

163

27.5M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Hennion & Walsh Asset Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Hennion & Walsh Asset Management, Inc. with notifications on news.